Signant Health’s eConsent solution played an important role in a global pharmaceutical company’s multinational phase 3 breast cancer study by streamlining multiple complicated site- and country-specific informed consent forms (ICFs) as well as facilitating IRB reviews.

The eConsent platform also helped the sponsor scale across six countries and eight languages, with some sites using multiple languages, by providing real-time study progress metrics and full visibility into ICFs for 215+ patients.

Download the case study for details.